vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and Limbach Holdings, Inc. (LMB). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $186.9M, roughly 1.5× Limbach Holdings, Inc.). Limbach Holdings, Inc. runs the higher net margin — 6.6% vs -45.7%, a 52.3% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 30.1%). Limbach Holdings, Inc. produced more free cash flow last quarter ($27.9M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs 25.3%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Limbach Flugmotoren is a Chinese-owned company based in Germany that produces aircraft engines.
GH vs LMB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $186.9M |
| Net Profit | $-128.5M | $12.3M |
| Gross Margin | 64.6% | 25.7% |
| Operating Margin | -43.0% | 9.4% |
| Net Margin | -45.7% | 6.6% |
| Revenue YoY | 39.4% | 30.1% |
| Net Profit YoY | -15.8% | 25.0% |
| EPS (diluted) | $-1.01 | $1.01 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $281.3M | $186.9M | ||
| Q3 25 | $265.2M | $184.6M | ||
| Q2 25 | $232.1M | $142.2M | ||
| Q1 25 | $203.5M | $133.1M | ||
| Q4 24 | $201.8M | $143.7M | ||
| Q3 24 | $191.5M | $133.9M | ||
| Q2 24 | $177.2M | $122.2M | ||
| Q1 24 | $168.5M | $119.0M |
| Q4 25 | $-128.5M | $12.3M | ||
| Q3 25 | $-92.7M | $8.8M | ||
| Q2 25 | $-99.9M | $7.8M | ||
| Q1 25 | $-95.2M | $10.2M | ||
| Q4 24 | $-111.0M | $9.8M | ||
| Q3 24 | $-107.8M | $7.5M | ||
| Q2 24 | $-102.6M | $6.0M | ||
| Q1 24 | $-115.0M | $7.6M |
| Q4 25 | 64.6% | 25.7% | ||
| Q3 25 | 64.7% | 24.2% | ||
| Q2 25 | 65.0% | 28.0% | ||
| Q1 25 | 63.3% | 27.6% | ||
| Q4 24 | 61.6% | 30.3% | ||
| Q3 24 | 61.1% | 27.0% | ||
| Q2 24 | 59.1% | 27.4% | ||
| Q1 24 | 61.2% | 26.1% |
| Q4 25 | -43.0% | 9.4% | ||
| Q3 25 | -37.3% | 7.2% | ||
| Q2 25 | -45.9% | 7.5% | ||
| Q1 25 | -54.6% | 5.9% | ||
| Q4 24 | -62.4% | 9.1% | ||
| Q3 24 | -61.3% | 8.1% | ||
| Q2 24 | -56.8% | 6.7% | ||
| Q1 24 | -59.2% | 5.5% |
| Q4 25 | -45.7% | 6.6% | ||
| Q3 25 | -35.0% | 4.8% | ||
| Q2 25 | -43.0% | 5.5% | ||
| Q1 25 | -46.8% | 7.7% | ||
| Q4 24 | -55.0% | 6.9% | ||
| Q3 24 | -56.3% | 5.6% | ||
| Q2 24 | -57.9% | 4.9% | ||
| Q1 24 | -68.2% | 6.4% |
| Q4 25 | $-1.01 | $1.01 | ||
| Q3 25 | $-0.74 | $0.73 | ||
| Q2 25 | $-0.80 | $0.64 | ||
| Q1 25 | $-0.77 | $0.85 | ||
| Q4 24 | $-0.90 | $0.81 | ||
| Q3 24 | $-0.88 | $0.62 | ||
| Q2 24 | $-0.84 | $0.50 | ||
| Q1 24 | $-0.94 | $0.64 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $11.3M |
| Total DebtLower is stronger | $1.5B | $30.5M |
| Stockholders' EquityBook value | $-99.3M | $195.7M |
| Total Assets | $2.0B | $381.1M |
| Debt / EquityLower = less leverage | — | 0.16× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $378.2M | $11.3M | ||
| Q3 25 | $580.0M | $9.8M | ||
| Q2 25 | $629.1M | $38.9M | ||
| Q1 25 | $698.6M | $38.1M | ||
| Q4 24 | $525.5M | $44.9M | ||
| Q3 24 | $585.0M | $51.2M | ||
| Q2 24 | $933.7M | $59.5M | ||
| Q1 24 | $1.0B | $48.2M |
| Q4 25 | $1.5B | $30.5M | ||
| Q3 25 | $1.1B | $56.3M | ||
| Q2 25 | $1.1B | $28.4M | ||
| Q1 25 | $1.1B | $23.7M | ||
| Q4 24 | $1.1B | $23.6M | ||
| Q3 24 | — | $20.5M | ||
| Q2 24 | — | $19.7M | ||
| Q1 24 | — | $19.4M |
| Q4 25 | $-99.3M | $195.7M | ||
| Q3 25 | $-354.5M | $181.6M | ||
| Q2 25 | $-305.5M | $170.5M | ||
| Q1 25 | $-250.8M | $161.1M | ||
| Q4 24 | $-139.6M | $153.5M | ||
| Q3 24 | $-60.1M | $142.2M | ||
| Q2 24 | $-1.6M | $133.0M | ||
| Q1 24 | $68.3M | $125.5M |
| Q4 25 | $2.0B | $381.1M | ||
| Q3 25 | $1.3B | $409.1M | ||
| Q2 25 | $1.3B | $343.0M | ||
| Q1 25 | $1.3B | $336.4M | ||
| Q4 24 | $1.5B | $352.1M | ||
| Q3 24 | $1.5B | $324.4M | ||
| Q2 24 | $1.6B | $303.9M | ||
| Q1 24 | $1.7B | $289.2M |
| Q4 25 | — | 0.16× | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 0.17× | ||
| Q1 25 | — | 0.15× | ||
| Q4 24 | — | 0.15× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.15× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $28.1M |
| Free Cash FlowOCF − Capex | $-54.2M | $27.9M |
| FCF MarginFCF / Revenue | -19.3% | 14.9% |
| Capex IntensityCapex / Revenue | 9.9% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 2.29× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $41.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-26.4M | $28.1M | ||
| Q3 25 | $-35.4M | $13.3M | ||
| Q2 25 | $-60.3M | $2.0M | ||
| Q1 25 | $-62.7M | $2.2M | ||
| Q4 24 | $-64.5M | $19.3M | ||
| Q3 24 | $-51.1M | $4.9M | ||
| Q2 24 | $-94.0M | $16.5M | ||
| Q1 24 | $-30.3M | $-3.9M |
| Q4 25 | $-54.2M | $27.9M | ||
| Q3 25 | $-45.8M | $12.8M | ||
| Q2 25 | $-65.9M | $1.2M | ||
| Q1 25 | $-67.1M | $11.0K | ||
| Q4 24 | $-83.4M | $18.0M | ||
| Q3 24 | $-55.3M | $4.6M | ||
| Q2 24 | $-99.1M | $13.2M | ||
| Q1 24 | $-37.2M | $-6.5M |
| Q4 25 | -19.3% | 14.9% | ||
| Q3 25 | -17.3% | 7.0% | ||
| Q2 25 | -28.4% | 0.8% | ||
| Q1 25 | -33.0% | 0.0% | ||
| Q4 24 | -41.3% | 12.5% | ||
| Q3 24 | -28.9% | 3.4% | ||
| Q2 24 | -55.9% | 10.8% | ||
| Q1 24 | -22.1% | -5.5% |
| Q4 25 | 9.9% | 0.1% | ||
| Q3 25 | 3.9% | 0.3% | ||
| Q2 25 | 2.4% | 0.6% | ||
| Q1 25 | 2.2% | 1.7% | ||
| Q4 24 | 9.4% | 0.9% | ||
| Q3 24 | 2.2% | 0.3% | ||
| Q2 24 | 2.9% | 2.7% | ||
| Q1 24 | 4.1% | 2.1% |
| Q4 25 | — | 2.29× | ||
| Q3 25 | — | 1.52× | ||
| Q2 25 | — | 0.26× | ||
| Q1 25 | — | 0.22× | ||
| Q4 24 | — | 1.96× | ||
| Q3 24 | — | 0.66× | ||
| Q2 24 | — | 2.77× | ||
| Q1 24 | — | -0.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
LMB
| Owner Direct Relationships Segment | $145.0M | 78% |
| General Contractor Construction Manager Relationships Segment | $41.9M | 22% |
